| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Bradycardia | D001919 | 13 associated lipids |
| Endometriosis | D004715 | 29 associated lipids |
| Myocardial Infarction | D009203 | 21 associated lipids |
| Proteinuria | D011507 | 30 associated lipids |
| Drug Hypersensitivity | D004342 | 20 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Fractures, Open | D005597 | 3 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Antimicrob. Chemother. (1)
- Clin. Diagn. Lab. Immunol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Laine L et al. | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. | 2003 | Am. J. Gastroenterol. | pmid:12650788 |
| Schaeverbeke T et al. | Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. | 2005 | Am. J. Gastroenterol. | pmid:16393213 |
| al-Assi MT et al. | Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. | 1994 | Am. J. Gastroenterol. | pmid:8053435 |
| Take S et al. | Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. | 2003 | Am. J. Gastroenterol. | pmid:14638340 |
| de Bortoli N et al. | Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. | 2007 | Am. J. Gastroenterol. | pmid:17313499 |
| Mohar A et al. | Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. | 2002 | Am. J. Gastroenterol. | pmid:12385434 |
| De Francesco V et al. | Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? | 2002 | Am. J. Gastroenterol. | pmid:12385470 |
| Cremonini F et al. | Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. | 2002 | Am. J. Gastroenterol. | pmid:12425542 |
| Rokkas T et al. | Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. | 2006 | Am. J. Gastroenterol. | pmid:16928256 |
| Sánchez-Delgado J et al. | Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. | 2008 | Am. J. Gastroenterol. | pmid:18564109 |
| Pilotto A et al. | In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. | 2000 | Am. J. Gastroenterol. | pmid:10710100 |
| Vakil N | H. pylori treatment: new wine in old bottles? | 2009 | Am. J. Gastroenterol. | pmid:19098845 |
| Watson JB and Moss SF | Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. | 2011 | Am. J. Gastroenterol. | pmid:22056576 |
| Rokkas T et al. | Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. | 2009 | Am. J. Gastroenterol. | pmid:19098844 |
| Zhou L et al. | A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. | 2014 | Am. J. Gastroenterol. | pmid:24642580 |
| Adamek RJ and Bethke TD | Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. | 1998 | Am. J. Gastroenterol. | pmid:9772056 |
| Ali' A et al. | A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. | 1999 | Am. J. Gastroenterol. | pmid:10445583 |
| Vakil N et al. | Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. | 1998 | Am. J. Gastroenterol. | pmid:9732920 |
| Chu KM et al. | A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. | 1998 | Am. J. Gastroenterol. | pmid:9732921 |
| Chiba N | Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. | 1996 | Am. J. Gastroenterol. | pmid:8855737 |
| Labenz J and Börsch G | Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7733070 |
| Gisbert JP et al. | Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. | 2008 | Am. J. Gastroenterol. | pmid:17764498 |
| Forné M et al. | Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. | 1995 | Am. J. Gastroenterol. | pmid:7733075 |
| Dohil R et al. | Effective 2-wk therapy for Helicobacter pylori disease in children. | 1997 | Am. J. Gastroenterol. | pmid:9040199 |
| Lerang F et al. | Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? | 1997 | Am. J. Gastroenterol. | pmid:9040200 |
| Odaka T et al. | Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. | 2002 | Am. J. Gastroenterol. | pmid:11922552 |
| Chey WD et al. | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. | 1997 | Am. J. Gastroenterol. | pmid:9317068 |
| Vakil N and Cutler A | Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10235192 |
| Scholte GH et al. | Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy. | 2002 | Am. J. Gastroenterol. | pmid:12135019 |
| Kim CG et al. | Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. | 2008 | Am. J. Gastroenterol. | pmid:17714557 |
| Sirimontaporn N et al. | Ten-day sequential therapy of Helicobacter pylori infection in Thailand. | 2010 | Am. J. Gastroenterol. | pmid:20010919 |
| Basu PP et al. | A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. | 2011 | Am. J. Gastroenterol. | pmid:21989146 |
| Hasegawa T et al. | Image of the month: Disseminated Nontuberculous Mycobacteriosis. | 2015 | Am. J. Gastroenterol. | pmid:26673493 |
| de Boer WA et al. | Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. | 1998 | Am. J. Gastroenterol. | pmid:9672338 |
| Shaheen N and Grimm IS | Fulminant hepatic failure associated with clarithromycin. | 1996 | Am. J. Gastroenterol. | pmid:8607519 |
| Vakil N | Helicobacter pylori treatment: a practical approach. | 2006 | Am. J. Gastroenterol. | pmid:16542285 |
| Santander C et al. | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. | 1996 | Am. J. Gastroenterol. | pmid:8759659 |
| Tursi A et al. | Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication. | 1996 | Am. J. Gastroenterol. | pmid:8759696 |
| Jarbol DE et al. | Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. | 2006 | Am. J. Gastroenterol. | pmid:16771937 |
| Bytzer P | Management of the dyspeptic patient: anything goes? | 2006 | Am. J. Gastroenterol. | pmid:16771938 |
| Manes G et al. | Eradication of Helicobacter pylori and dosages of esomeprazole. | 2006 | Am. J. Gastroenterol. | pmid:16771971 |
| Sonnenberg A et al. | The effect of antibiotic therapy on bleeding from duodenal ulcer. | 1999 | Am. J. Gastroenterol. | pmid:10201462 |
| Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
| van der Wouden EJ et al. | One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. | 1998 | Am. J. Gastroenterol. | pmid:9707042 |
| Laine L et al. | Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. | 2000 | Am. J. Gastroenterol. | pmid:11151867 |
| Kadayifçi A et al. | Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease. | 1995 | Am. J. Gastroenterol. | pmid:7872307 |
| Laine L et al. | Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. | 1997 | Am. J. Gastroenterol. | pmid:9399755 |
| Srinivasan R and Minocha A | Cure of Helicobacter pylori: a hidden curse? | 1997 | Am. J. Gastroenterol. | pmid:9399784 |
| Veldhuyzen van Zanten S et al. | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. | 2003 | Am. J. Gastroenterol. | pmid:14499772 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |